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Background: Epstein-Barr virus (EBV) is associated with 20-40% of Hodgkin’s Lymphoma (HL) cases. EBV-encoded
latent membrane protein 1 (LMP1) is a well-known oncogenic protein and two C-terminal deletion variants,
del30-LMP1 and del69-LMP1, have been described in animal models to be more tumorigenic than the wild-type
form. This work aims to detail the implication of LMP1 in the development of HL and to characterize the particular
effects of these variants.
Methods: We established HL-derived cell lines stably transfected with the pRT-LMP1 vector coding for the EBNA1
gene and allowing expression of the different LMP1 variants under the control of a doxycyclin-inducible promoter.
Communication between cells was assessed by measuring the expression of various pro-inflammatory cytokines by
flow cytometry after intracellular LMP1 and cytokine double staining. Proliferative properties of LMP1 variants were
also compared by studying the repartition of cells in the different phases of the cell cycle after EdU incorporation
combined to LMP1 and DAPI staining.
Results: All LMP1 proteins induced the expression of several pro-inflammatory cytokines such as TNF-α, TNF-β, IL-6,
RANTES/CCL5 and IFN-γ. However, the del30-LMP1 variant induced cytokine expression at a lower level than the
other variants, especially IFN-γ, while the del69-LMP1 variant stimulated greater cytokine expression. In addition, we
measured that all LMP1 proteins greatly impacted the cell cycle progression, triggering a reduction in the number
of cells in S-phase and an accumulation of cells in the G2/M phase compared to the HL-non induced cells.
Interestingly, the del30-LMP1 variant reduced the number of cells in S-phase in a significantly greater manner
and also increased the number of cells in the G0/G1 phase of the cell cycle.
Conclusion: Weak IFN-γ expression and specific alteration of the cell cycle might be a way for del30-LMP1 infected
cells to escape the immune anti-viral response and to promote the development of cancer. The differences
observed between the LMP1 variants reflect their own oncogenic properties and eventually impact the
development of HL.
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EBV is an ubiquitous tumor-causing virus infecting more
than 90% of human adults worldwide with a life-long in-
fection in B lymphocytes asymptomatically [1]. EBV infec-
tion in HRS cells presents a type II latency program,
characterized by the expression of the latent membrane
protein 1 (LMP1) and two other viral proteins, EBNA1
and LMP2 in addition to small RNAs, termed EBER 1 and
2 [2]. LMP1 is a multifunctional oncoprotein essential
for EBV-induced B-cell proliferation and transformation
in vitro [3], as it shares several features with CD40, a
member of the tumor necrosis factor receptor family
(TNFR). LMP1 activates the transcription factor nuclear
factor-κB (NF-κB) by promoting turnover of IκBα, an
important inhibitor of NF-κB, conferring the cells a pro-
tection against apoptosis. A direct link between LMP1
and cell cycle progression has also been shown in several
studies although they were essentially focused on NPC
cells or Burkitt lymphoma cell lines [4-7].
In the EBV-associated pathologies, different variants of
LMP1 have been described. For example, a 30-bp dele-
tion variant at the C terminal and corresponding to the
CAO variant isolated from a NPC patient, was found to
have increased potential to transform rodent fibroblasts
and to induce tumors in nude mice when compared to
wild-type LMP1 [8]. A 69-bp deletion LMP1 variant has
also been described in NPC [9] and other lymphopro-
liferative disorders such as HL [10]. These deletions do
not interfere with the stimulation of NF-κB [11]. How-
ever, the presence of such variants associated to the
pathogenesis of several diseases leads to the hypothesis
that polymorphisms within LMP1 gene might influence
the susceptibility to develop EBV-associated tumors.
Hodgkin Lymphoma (HL) is a B cell lymphoma, charac-
terized by a minority of neoplastic cells, the Hodgkin and
Reed-Sternberg cells (HRS cells), and an extensive inflam-
matory background. Classical HRS cells derive from post-
germinal center B cells, destined for apoptosis in the B cell
selection process because of the lack of successful im-
munoglobulin gene rearrangement. In Western world,
20-40% of HL are associated with Epstein-Barr Virus
(EBV) while in developing countries it reaches 70% [12].
Interestingly, EBV has been detected in 80-100% of HL
arising in HIV patients, supporting the notion that this
virus plays a pivotal role in the pathogenesis of this tumor
[13]. Moreover, presence of the 30-bp deletion in LMP1
has been frequently associated with the HL disease in HIV
infected individuals [13,14]. Recently, LMP1 has been
shown to increase the DDR1 tyrosine kinase receptor in
germinal center B cells, activating the expression of pro-
inflammatory mediators and protecting lymphoma cells
from cell death [15]. Besides, many studies have docu-
mented that HL is associated with disturbed cytokine pro-
duction [16]. Cytokine and chemokine production maynot only promote growth of HRS cells and help to evade
immune surveillance, but they also cause the characte-
ristic histology and the clinical symptoms of HL [17].
Cross-talk between HRS cells and surrounding lympho-
cytes has been studied for many years, and this interaction
appeared to play an important role for the pathogenesis of
HL [18]. Few studies have documented the impact of EBV
infection on HL development. HL frozen tissues [19] or
derived cell lines infected by EBV in vitro or transiently
transfected by a constitutive expressed LMP1 vector were
used [20-24]. However, results obtained from these studies
were difficult to interpret since either there were not
quantitative or the cell lines did not express LMP1 until a
membrane signal was applied (CD40 ligand and IL4), lea-
ding to morphological studies where LMP1 was linked to
the formation of multinuclear cells or showing differen-
tially expressed proteins by microarray RNA assays, not
confirmed by protein expression techniques. Other studies
about LMP1 genetic diversity from samples derived from
HL patients focusing mainly on LMP1 variant origin and
activation of the NF-κB pathway were also conducted
[25-27]. However, the impact of the LMP1 polymorphism
on the HL cells has not been documented.
In this study, we investigated whether WT-LMP1 and
the deletion variants del30-LMP1 and del69-LMP1 could
modulate cytokine expression and cell cycle progression
in KMH2 – a HL derived cell line – to analyze the im-
pact of LMP1 polymorphism on the development of HL.
Results
Characterization of the KMH2-pRT-LMP1 established cell
lines
In order to study the impact of different LMP1 deletion
variants on the behavior of the KMH2 HL cell line, we
established three cell lines stably transfected with the
pRT-LMP1 vector coding for either the wild-type form of
LMP1 (WT-LMP1) or deleted variants (del30-LMP1;
del69-LMP1) (Figure 1a). After electroporation and three
weeks of hygromycin selection, presence of the plasmid
and expression of viral genes were assessed by inducing
cells with doxycyclin for 24 h. Expectedly, RT-PCR
showed that the EBNA1 gene was constitutively expressed
in the three KMH2-pRT-LMP1 cell lines but not in the
KMH2 cells. LMP1 was only expressed in presence of
doxycyclin, as shown by RT-PCR (Figure 1b). A shift can
be observed between the three PCR products of the LMP1
amplification corresponding to the 30-bp and 69-bp dele-
tions in the LMP1 gene. LMP1 inducible-expression was
also observed by western-blotting (Figure 1c) showing no
significant difference in LMP1 expression normalized to
actin (actin/LMP1 ratio: WT-LMP1 ×1.89; del30-LMP1 ×
1.54; del69-LMP1 × 1.75). The precise number of cells
expressing LMP1 in the three cell lines was determined
by flow-cytometry (Figure 1d). On average, 25% of the
Figure 1 Characterization of the KMH2-pRT-LMP1 established cell lines. (a) Linear representation of WT-LMP1 and the 10 and 23 amino-acid
deletions corresponding to the del30 and del69-LMP1 variants. (b) RT-PCR or (c) Western blot of EBNA1 and LMP1 in non-induced cells and in
doxycyclin-induced cells expressing WT-LMP1, del30-LMP1 and del69-LMP1 variants. 293-HEK cells transiently transfected with pcDNA-WT-LMP1
were used as positive control for immunoblotting. (d) Comparison of LMP1 expression by flow-cytometry in the KMH2-pRT-LMP1 cells.
Doxycyclin-induced cells are represented in green and non-induced cells in black. Data are representative of 3 experiments.
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del30-LMP1 cells and 20% of the KMH2-pRT-del69-
LMP1 expressed LMP1 compared to non-induced cells.
These low rates of cells expressing LMP1 could be due to
heterogeneity in the LMP1 expression level or to the pre-
sence of hygromycin resistant KMH2 cells. Attempts
to enrich or clone LMP1 expressing cells (by selecting
NGFR-expressing cells or subcloning) were unsuccessful
since KMH2 cells express low level of endogenous NGFR
and did not grow at low density. In order to study the im-
pact of LMP1 variants on HL cells, we used flow cyto-
metry to gate selectively the LMP1 positive cells among
the established cell lines in all the next experiments.
LMP1 induces expression of several cytokines in KMH2
cells
Communication between HRS cells and the surrounding
immune cells plays a major role in the development of HL.
To examine the influence of LMP1 on HRS cytokine secre-
tion, we studied intracellular cytokine expression by flow
cytometry in KMH2 cells expressing LMP1 or stimulated
by phorbol-myristate-acetate and ionomycin (PMA-iono)
as positive control. We choose to study different cytokines
involved in inflammatory processes, recruitment of im-
mune cells and HL pathogenesis. After 24 h of doxycyclin
induction, all KMH2-pRT-LMP1 cells expressed TNF-α,
TNF-β, IL-6, RANTES/CCL5 and IFN-γ (Table 1). On the
contrary, none of the LMP1 variants induced expression of
TGF-β, IL-8, IL-9, IL-1α and IL-1RA, while stimulation of
KMH2 with PMA-ionomycin induced all these cytokines
(Table 1). Of note that production of cytokines was not
modified by addition of doxycyclin in the non-transfected
KMH2 (data not shown). Thus, LMP1 induced the ex-
pression of several cytokines in HL cells, promoting the
establishment of an inflammatory microenvironment in
favor of the tumor development.Table 1 Cytokine expression induced in Hodgkin’s lymphoma











Cytokine expression was assessed by flow cytometry analysis after induction of KMdel30-LMP1 induces cytokine expression at a lower level
than the other LMP1 variants
Furthermore, we investigated the effect of the different
LMP1 deletion variants on HRS cytokine secretion. LMP1
and cytokine labeling dot plots are shown in Additional
file 1. IFN-γ was significantly induced by WT-LMP1 (21.5
± 5.8%) and del69-LMP1 (27.2 ± 3.4%) compared to LMP1
non-expressing cells (3.5 ± 3.3%) (Figure 2a). Interestingly,
del30-LMP1 increased the number of IFN-γ producing
cells to a significantly lesser extent (7.1 ± 3.4%) compared
to the WT-LMP1 and del69-LMP1 forms, although to a
significant amount compared to the non-induced cells.
Likewise, the three LMP1 variants were able to induce
IL-6 expression compared to non-induced cells (1.1 ±
1.0%; Figure 2b). However, the number of del30-LMP1
cells was significantly lower (30.5 ± 6.9%) than the two
other variants WT-LMP1 (41.9 ± 6.9%) and del69-LMP1
(57.4 ± 12.9%). In addition, a significant greater number of
del69-LMP1 cells expressed IL-6 compared with the other
variants (Figure 2b). The same observation can be made
with RANTES/CCL5, whose expression is induced by all
LMP1 variants compared to non-induced cells, and in
a significantly higher proportion with the del69-LMP1
variant (control cells 11.7 ± 3.4%, WT-LMP1 34.0 ±
3.8%, del30-LMP1 27.7 ± 5.5%, del69-LMP1 46.2 ± 6.3%)
(Figure 2c). Two members of the TNF family were then
analyzed. TNF-β expression was induced by all LMP1
variants compared to KMH2 control cells (13.4 ± 5.4%)
with a significantly smaller percentage of del30-LMP1
cells expressing TNF-β (52.0 ± 4.0%) in relation to the two
other variants WT-LMP1 (62.3 ± 6.4%) and del69-LMP1
(71.7 ± 5.6%) (Figure 2d). TNF-α expression was induced
by LMP1 compared to non-induced KMH2 cells (3.0 ±
1.6%; Figure 2e). No significant difference could be
observed between the LMP1 variants (WT-LMP1 21,7 ±
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Figure 2 Cytokine expression is differently regulated by LMP1 variants. Cytokines expressed by KMH2-pRT-LMP1 cells (non-induced, WT, del30
and del69) were intracellularly stained and detected by flow-cytometry 24 h after induction of LMP1 expression. The percentages of cells expressing
(a) IFN-γ, (b) IL-6, (c) RANTES/CCL5, (d) TNF-β and (e) TNF-α were compared. All cytokines were significantly more expressed in LMP1 expressing cells
compared to non-induced cells with an ANOVA analysis (of note that expression of IFN-γ was significantly higher in KMH2-pRT-del30-LMP1 cells
compared to the control unstimulated KMH2 cells with an ANOVA analysis followed by a Dunnett post-test). Supplemental data showing LMP1 and
cytokine labeling dot plots are provided as Additional file 1.
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pression at a lower level compared with both forms:
WT-LMP1 and del69-LMP1. Nonetheless, del69-LMP1
seemed to induce more cytokine expression than the
two other LMP1 variants.
LMP1 variants influence differently cell cycle progression
The LMP1 deletion variants have been shown to be
more tumorigenic than the WT-LMP1 [8,28]. In order
to study the effect of LMP1 variants on the cell cycle
progression in the KMH2 cell line, percentages of cells
in the different phases of cell cycle were determined byflow cytometry, using DAPI and EdU incorporation as
shown in Figure 3a. Twenty four hours after induction,
all LMP1-expressing cells show a significantly smaller
percentage of cells in S phase than the control cells
(Figure 3b). We verified that the observed effects were
actually due to the expression of LMP1 rather than the
presence of doxycyclin in the medium by inducing non-
transfected KMH2 cells with doxycyclin for 24 h. Indeed,
no difference could be detected between doxycyclin-
induced and non-induced KMH2 cells (data not shown).
It is worth noting that the expression of del30-LMP1 va-





























































Figure 3 (See legend on next page.)
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Figure 3 LMP1 influences cell cycle progression in the KMH2 Hodgkin’s lymphoma cell lines. Percentage of cells in the different phases of
cell cycle was assessed by measurement of EdU incorporation and DAPI staining by flow cytometry after induction of LMP1 expression in the
KMH2-pRT-LMP1 cell lines (non-induced, WT, del30 and del69). (a) Example of cell cycle dot plot, (b) Cells in S phase, (c) Cells in G0/G1 phase
and (d) Cells in G2/M phase. (e) Repartition of cells in the different phases of the cell cycle represented in a stacked histogram.
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If all LMP1 variants had an enhanced percentage of cells
in G2/M phase compared to the control cells (6.9 ± 1.7%),
WT-LMP1 induced a significantly higher accumulation of
cells in G2/M phase (14.2 ± 1.6%) than the deletion va-
riants del30-LMP1 (9.9 ± 1.6%) and del69-LMP1 (9.0 ±
0.8%) (Figure 3c). Interestingly, expression of del30-LMP1
promoted a significant accumulation of cells in G0/G1
phase (56.9 ± 2.6%) compared to the control cells (40.5 ±
4.4%) while WT-LMP1 (37.8 ± 0,8%) and del69-LMP1
(42.6 ± 2.6%) did not differ from non-induced cells
(Figure 3d). Percentage of sub-G0/G1 cells was slightly
increased by the expression of WT-LMP1 (3.16 ± 1.76%)
or del69-LMP1 (2.85 ± 0.99%) protein compared to con-
trol cells (1.14 ± 0.67%)(data not shown). However, num-
ber of del30-LMP1 cells in sub-G0/G1 phase was not
significantly different compared with control cells (2.33 ±
0.54%).
Thus, all variants reduced the S phase and accumu-
lated cells in the G2/M phase, suggesting a blockade at
the G1/S checkpoint and a block to completion of mi-
tosis in the KMH2 cells (Figure 3e). The del30-LMP1
variant significantly reduced the number of S-phase cells
and further increased the G0/G1-phase cells.
Discussion
In the context of HL, where tumor cells represent only
0.1 to 1% of the cells surrounded by fibroblasts and im-
mune cells, communication between cells mediated by
cytokines and chemokines is of upmost importance.
LMP1 is a well-known oncogene involved in many cel-
lular signaling pathways and thus able to interfere in
cytokine secretion. Previously, LMP1 has been shown to
induce IL-6 and IL-8 secretion in epithelial cells [29] via
the NF-κB pathway [30] and IL-10 in Burkitt lymphoma
cells [31]. In LCL, LMP1 triggers cell proliferation by in-
ducing cytokines such as CCL3 and CCL4 through the
JUN-kinase pathway [32], and also uses the NF-κB path-
way to stimulate IFN secretion [33]. In this study, we
showed that LMP1 induced significantly the expression
of several cytokines in LMP1 positive KMH2 HL-derived
cells, such as IFN-γ, IL-6, RANTES/CCL5, TNF-β and
TNF-α. These cytokines are mainly pro-inflammatory,
attracting immune cells in the microenvironment and
known to be implicated in the development of HL
[17,34]. Vockerodt et al. [24] showed that LMP1 induced
high levels of IL1, IL8 and RANTES mRNAs in primaryhuman tonsillar germinal center B cells (CD10+ cells).
We did not find IL8 and IL1 elevated amounts in the
LMP1 positive KMH2 cell lines. Whether this discre-
pancy is due to the different techniques used or to the
cells still remains to be determined.
Little is known about the influence of LMP1 on cytokine
production in the particular context of HL. An histological
study showed that IL-6 was more often expressed in
LMP1-positive HRS cells compared to the negative ones
[35]. Showing differences in cytokine expression between
the three LMP1 positive forms could be of interest to HL.
While a significantly higher number of del69-LMP1 cells
expressed IL-6 and RANTES, del30-LMP1 cells expressed
IFN-γ, IL-6 and TNF-β in a significantly lesser extent than
the other variants. IFN-γ is involved in the anti-viral re-
sponse against EBV-infected cells. Weak IFN-γ expression
might be a way for del30-LMP1 infected cells to escape
the immune anti-viral response. Besides, on the one hand,
the presence of cytokines is necessary for cell survival and
tumor promotion. Yet, on the other hand, an excessive
cytokine secretion stimulates the recognition and degra-
dation of EBV-infected cells by the immune system. The
low level of cytokines expressed in del30-LMP1 KMH2
cells could be a mechanism for EBV to promote the deve-
lopment of HL while escaping the immune surveillance.
These observations are consistent with the high frequency
of del30-LMP1 variant observed among HIV positive peo-
ple developing a HL [13,14]. On the contrary, the high
proportion of del69-LMP1 HL cells to express pro-inflam-
matory cytokines could trigger their recognition by the
immune system and would explain the low frequency of
the del69-LMP1 variant in vivo, described only sporadi-
cally in NPC or some lymphoproliferative diseases. Prog-
nostic significance of pretreatment serum cytokines in HL
has been described [36]. In particular, they show that
serum levels of IL6 and IL2R may be used to identify pa-
tients with HL at risk for early-disease relapse. Since we
found that IL6 was less induced by the del30-LMP1 va-
riant, it thus would be of great interest to determine
in vivo, if the IL6 level in serum may be linked to the pre-
sence of del30-LMP1 variant and of early-disease relapse.
Oncogenic LMP1 has also a great influence on cell pro-
liferation and survival by contributing to cell cycle pro-
gression. Here we show for the first time in HL cells, that
all LMP1 variants interfered with cell cycle progression.
LMP1 caused a decrease in the S-phase cell population,
particularly significant with the del30-LMP1 variant and
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variant provoked an additional accumulation of cells in
the G0/G1 phase. These observations were consistent with
previous studies performed in NPC cell lines and LCLs
with WT-LMP1 or a NPC-derived variant, carrying the
30 bp deletion [4,7]. LMP1 has been described to impair
G2 checkpoint leading to a possible accumulation of cells
with unrepaired DNA damages [4] or to promote cell
cycle progression by accelerating the G1/S transition
[5,37]. On the other hand, LMP1 has also been described
to have cytostatic or even cytotoxic effects when expressed
at high levels [7,38]. A recent work suggests that the abi-
lity of LMP1 to exert both cytotoxic and pro-proliferative
properties is necessary during the transformation process
[39]. While LMP1 induces cell death in the microenviron-
ment, only EBV infected cells expressing the oncogenic
LMP1 survive [39]. The fact that LMP1 variants do not
elicit the same effect on cell cycle progression suggests
that they have different impact on cell cycle checkpoints.
This could directly reflect on their oncogenic potential.
Besides, cytokines themselves can influence the cell cycle
progression. For example, IL-8 is often overexpressed in
cancers and contributes to the tumor development by
promoting the G1/S transition of cell cycle [40]. It would
be interesting to further investigate the cellular mechan-
ism involved in cell cycle progression with each LMP1
variant and particularly the impact of the LMP1-induced
cytokines.
In conclusion, this study brings new insights into the
impact of LMP1 on cytokine expression and cell cycle
progression in HL. We highlight differences between
LMP1 variants which could partly be responsible for
their respective oncogenic properties and explain their
implication as risk factors in the development of HL.
Materials and methods
Plasmid constructs
We performed an overlapping PCR using the p2167
plasmid (kindly provided by W. Hammerschidt, Munich,
Germany), in order to create the 30-bp and 69-bp dele-
tions in the BNLF1 gene coding for LMP1 [41]. The
p2167 plasmid contains 9.5 kb of the EBV genome, as
described [42]. Two DNA fragments surrounding the
deletions (respectively in position 1190-1229 and 1161-
1229) were amplified by PCR with a high fidelity poly-
merase (Pfu, Promega, Fitschburg, WI, USA). The fol-











First, two PCRs were performed with 50 ng of the
p2167 plasmid in a total volume of 50 μl, with primers
P1 + P2a and P3a + P4 for the 30-bp deletion or P1 + P2b
and P3b + P4 for the 69-bp deletion. After 5 min of de-
naturation at 95°C, 10 cycles of 30 sec at 95°C, 30 sec at
55°C and 2 min at 72°C were carried out, followed by an
elongation step for 5 min at 72°C. PCR products were
purified by QIAEX purification kit (Qiagen, Hilden,
Germany), quantified by the nanodrop system (Labtech,
Uckfield, United-Kingdom) and equimolarly mixed to be
submitted to a second PCR. After 10 cycles with the
same program but without primers, allowing the first
two PCR products to hybridize, external primers P1 and
P4 were added for another 20 cycles. The final 1.6 kb
PCR product containing the 30-bp or 69-bp deletion
was reintroduced into the original p2167 plasmid in the
NheI and Bst1107I restriction sites and subcloned into
the Sfi-I sites of the pRT-LMP1 vector (kindly provided
by J. Feuillard, Limoges, France) with the In-Fusion HD
cloning kit (Clontech, Mountain View, CA, USA). This
vector includes the EBNA1 and hygromycin B resistance
genes, that favour maintenance of the vector as an epi-
some in the cells, and allow selection of transfected cells
respectively. A bidirectional tetracyclin-inducible pro-
moter drives the expression of LMP1 and NGFRt [43].
The pcDNA-WT-LMP1 plasmid is a kind gift from F.
Grässer (Hambourg, Germany).
Cell culture, transfection and induction
293-HEK cells (human embryonic kidney cell line) were
cultured in DMEM supplemented with heat inactivated
fetal bovine serum 10% and antibiotics (100 units/ml
penicillin/streptomycin and 1 μg/ml ofloxacin). KMH2
cells (EBV-negative Hodgkin Lymphoma-derived cell line
obtained from DSMZ, Braunschweig, Germany) were
cultured in RPMI supplemented with 10% heat inactivated
fetal bovine serum and antibiotics (100 units/ml peni-
cillin/streptomycin, 1 μg/ml ofloxacin), at 37°C in a 5%
CO2 atmosphere. For transient transfection of pcDNA-
WT-LMP1 in 293-HEK cells, 5.105 cells were plated in a
35-mm petri dish and transfected with Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) in the ratio of 10 μl
transfection reagent for 4 μg of DNA, following the
manufacturer’s instructions. Establishment of KMH2
cell lines stably transfected with the three pRT-LMP1
plasmids (pRT-WT-LMP1, pRT-del30-LMP1 and pRT-
del69-LMP1) was performed with the Amaxa electro-
poration system (Amaxa, Cologne, Germany), according
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cells were electroporated with 5 μg of DNA, using the
Nucleofactor kit-T (Amaxa) and the T-001 program. Cells
were then resuspended in 5 ml of fresh RPMI with 20%
FBS, supplemented with 1X non-essential amino-acids,
10 mM Hepes and 1 mM sodium pyruvate. Hygromycin
was introduced in the medium 48 h after the transfection
at 200 μg/ml. After three weeks of selection, LMP1 ex-
pression was assessed by flow cytometry after inducing
the cells with 1 μg/ml doxycyclin (Clontech) for 24 h, as
described elsewhere [43].
Western-blotting
Five millions KMH2-pRT-LMP1 cells were grown in pres-
ence or not of doxycyclin for 24 h. Cells were lysed in a
buffer composed of 50 mM Tris pH 6.8, 2% SDS, 10%
glycerol and protease inhibitors. Lysates were sonicated
and total proteins were quantified with BCA kit (Pierce,
Rockford, IL, USA) according to the manufacturer’s in-
structions. Fifty micrograms of total proteins were sepa-
rated on a 9% SDS-PAGE gel, transferred on a PVDF
membrane and revealed by western-blot analysis with an
anti-LMP1 antibody (monoclonal CS.1-4, Dako, Glostrup,
Denmark, 1:100) and a rabbit polyclonal anti-actin (Sigma,
St Louis, MO, USA; 1:400). Secondary HRP-conjugated
anti-mouse (1:20000), anti-rabbit antibodies (1:10000)
were purchased from Invitrogen). The signal was de-
veloped by Supersignal West Pico Chemiluminescent
Substrate (Pierce). The intensity of protein bands was
quantified with Adobe Photophop CS3 software.
RNA extraction and RT-PCR
Total RNA was extracted from 5.106 KMH2-pRT-LMP1
cells with TRI-Reagent (Euromedex, Souffelweyersheim,
France), quantified with a nanodrop ND1000 instrument
system (Labtech) and treated with Turbo-DNase (Ambion,
Austin, TX, USA). cDNA was synthesized from 1 μg total
RNA with random hexamers, using the superscript III
(Invitrogen) in a total volume of 20 μl. PCRs were then
performed on 1 μl of cDNA, with 0.25U of the Phusion
polymerase (Thermo-Scientific, Waltham, MA, USA) in
the provided buffer, in presence of 200 μM dNTP and






actin-reverse, 5′-CTGGGTCATCTTCTCGCG-3′. After a
denaturation step of 3 min at 94°C, the following cycle
was applied to the samples : 30 sec at 94°C, 30 sec at 60°C
(for EBNA1, TH was 56°C), 30 sec at 72°C, repeated 26
times for the actin amplification and 30 times for LMP1
and EBNA1 amplifications. A final elongation step wasperformed for 5 min at 72°C. PCR products were migrated
on a 2% agarose gel in 1X TAE buffer and visualized with
ethidium bromide staining (Invitrogen).
LMP1 staining and intracellular cytokine detection
KMH2 cells were either treated by doxycyclin (1 μg/ml) to
induce LMP1 expression or stimulated with 50 ng/ml PMA
(Sigma) and 1 μg/ml ionomycin (Sigma) to be used as
positive control for cytokine expression during 24 h.
Throughout the last 4 h of doxycyclin or PMA-ionomycin
induction, cells were treated with 10 μg/ml brefeldin A
(BioLegend, San Diego, CA, USA) and 2 μM monensin
(Sigma) to block secretion of cytokines. Cells were collected
and fixed with fixation buffer (BioLegend) for 20 min at
room temperature. Cells were then permeabilized by two
centrifugations (for 8 min at 350 g) with permeabilization
wash buffer (BioLegend) allowing sequential double immu-
nolabeling of LMP1 and cytokines of interest. LMP1 stain-
ing was performed primarily as follows: cells were saturated
for 30 min in 100 μl RPMI containing 10% human plasma
(kindly provided by EFS Rhône-Alpes, Grenoble, France)
and 0.1% triton X-100, incubated for 30 min with the anti-
LMP1 antibody (1:100) and washed twice with 5 ml of
RPMI. Cells were then incubated for 30 min with an Alexa
A488 or A594-conjugated anti-mouse antibody (Invitrogen,
1:2500) and washed twice with 5 ml of RPMI. An anti-
mouse secondary antibody free Fab sites was finally satured
with a mouse hybridoma supernatant (clone D3210, kindly
provided by E. Drouet, UVHCI, Grenoble, France). In a sec-
ond step, intracellular cytokine staining was carried out by
resuspending cells in 100 μl of permeabilization wash buffer
supplemented with the anti-cytokine antibody and incu-
bated for 20 min at room temperature, protected from light.
Cells were then washed twice with 2 ml of permeabilization
wash buffer and finally resuspended in cell staining buffer
(BioLegend) for flow cytometry analysis on a MACSQuant
VYB (Miltenyi Biotech GmbH, Bergisch Gladbach,
Germany). Anti-cytokine antibodies used were APC-conju-
gated anti-human TNF-α (clone Mab11) or its mouse iso-
type control (clone MOPC21), PE-conjugated anti-human
IL-6 (clone MQ2-13A5), anti-human IL-8 (E8N1), anti-
human TNF-β (clone 359-81-11), anti-human TGF-β
(TW4-2 F8), anti-human IL-1α (364-3B3-14), rat isotype
control (clone RTK2071) and mouse isotype control (clone
MOPC21) from BioLegend, PE-conjugated anti-human
IFN-γ (clone 4S.B3), anti-human IL-9 (MH9A3) and anti-
human RANTES/CCL5 (clone 2D5) from BD Pharmingen
(San Diego, CA, USA), or FITC-conjugated anti-human
IL1-RA (CRM17) and its mouse isotype control (P3.6.2.8.1)
from eBioscience (San Diego, CA, USA).
Cell cycle and proliferation
In order to determine the percentage of cells in the diffe-
rent phases of cell cycle, we used the EdU-click 555 (Jena
Sueur et al. Virology Journal 2014, 11:94 Page 10 of 11
http://www.virologyj.com/content/11/1/94Bioscience, Jena, Germany) combined with LMP1 and
DAPI staining. EdU is a nucleoside analogue to thymidine
incorporated into DNA, it reveals the proliferating cells in
S phase. DAPI measures the total quantity of DNA in the
cells and the LMP1 labelling enables to select only the
LMP1-expressing cells for our study. Cells were induced
with doxycyclin for 24 h and, during the last 150 min,
10 μM EdU was added in the culture medium. Cells were,
then, fixed with fixation buffer and permeabilized with
permeabilization wash buffer (BioLegend). For EdU reve-
lation, cells were resuspended in the cocktail-click con-
taining TAMRA-azide, incubated for 30 min at room
temperature protected from light and washed twice with
6 ml PBS. LMP1 staining was performed as described pre-
viously for intracellular cytokine detection and cells were
finally incubated in PBS with 1 g/L glucose, DAPI 1:1000
and 100 μg/ml RNAseA until flow cytometry analysis.
Statistical analysis
Means, standard deviations and p-values were calculated
with the GraphPad InStat3 software (San Diego, CA,
USA). All bar graphs represent means as per at least three
independent experiments for cytokine detection and at
least five independent experiments for cell cycle studies.
Error bars represent standard deviations. To assess statis-
tical differences, means were compared through a one-way
ANOVA test followed by a Tukey post-test for multiple
comparison significance test between the analyzed groups.
When specified, for single comparison of a population
with the control cell group, the ANOVA test was followed
by a Dunnett post-test. * stands for p < 0.05, ** for p < 0.01
and *** for p < 0.001.
Additional file
Additional file 1: Cytokine expression by KMH2-pRT-LMP1 expressing
cells. Cytometric data plots are presented for each cytokine expressed by
the three KMH2-pRT-LMP1 cell lines, with or without induction of LMP1
expression, compared to an isotypic control antibody. X-axis shows LMP1
expression while Y-axis represents cytokine expression. Percentages of cells
in each quadrant are given in black. LMP1-positive cells (right upper and
lower quadrants) are selectively gated and considered 100% in order to
calculate the percentage of LMP1-positive cells expressing the cytokine of
interest, indicated in red. Experiments have been conducted in triplicates
and pictures shown here represent only one out of three experiments.
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